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In our current study thirteen new 2,4-dinitrophenyl hydrazone derivatives 1–13 have been evaluated for alpha amylase 
activity. The molecular docking results indicate that compounds potentially bind in the catalytic site of the enzyme with 
excellent result. Molecular Operating Environment (MOE) software was used for docking study. 2,4-Dinitrophenyl 
hydrazone 1-13 have been obtained under reflux conditions by reacting dinitrophenyl hydrazine in methanol with different 
aromatic as well as aliphatic aldehydes in the presence of acetic acid act as a catalyst. The current results have shown that 
compounds 5 (IC50 =12.16µg/mL), 6 (IC50 =15.03µg/mL), and 12 (IC50 =16.42 µg/mL) have been found to be the more 
potent alpha amylase inhibitors as compared to the standard acarbose (IC50 = 42.47µg/mL). These compounds may provide 
better leads for alpha amylase inhibitor and further assessment of these compounds can be of great help in the discovery of 
new antidiabetic drugs. 
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A German chemist, Joseph Schiff Ugo Hugo, modern 
Chemistry’s father1 reported Schiff bases having 
(C = N) azomethine functionality and are unique 
organic compound generally called imine2. The 
ketones or, aldehydes carbonyl compounds react with 
amines via a condensation reaction to produce an 
imine, Schiff base3. It contains nitrogen carbon double 
bond where the nitrogen does not have any hydrogen, 
but only possesses aryl/alkyl group while the carbon 
possesses R2=H called azomethine secondary 
aldamine. R3 is substituted phenyl, phenyl derived 
aniline4. General structure of Schiff bases is shown 
in Figure 1. 
Compounds containing azomethine or imine 
functionality showed important biological activities 
due to the presence of imine reactive group found in 
natural, derived compounds or synthesized 
compounds5. A wide range of biological activities 
have been attributed to Schiff bases such as antiviral 
activity, antibacterial activity, antifungal activity, 
antimalarial activity6-8, etc. Derived aromatic 
aldehyde and amine Schiff bases are widely used in 
analytical, inorganic, and biological chemistry9-11. 
Many novel biological activities have been reported 
with a significant result on synthesized Schiff base 
such as antitumor activity12-15, antioxidant activity16-18, 
anti-inflammatory activity19,20 and lipid lowering 
ability18. Schiff bases play a key role in the medicinal 
and pharmaceutical field for different activities19,21-23. 
Urease inhibitory activity was also reported with 
significant results24-26. Schiff bases have a lower side 
effect and present novel behavior27,28. Our current 
study is focused on the evaluation of synthesized 
Schiff bases for alpha amylase inhibition activity. 
Alpha amylase anti-diabetic activity 
The major health problem of the twenty first 
century around the world is diabetic disease 
associated with hyperglycemia, hypertension, 
gastroparesis, ketoacidosis, and nephropathy, and 
affected around 15 million people globally29. Diabetes 
are mainly type – II (In which blood sugar level 
process effected), and in type – I (No or, little insulin 
production occur from pancreas)30,31. Oxidative stress 
is mainly held responsible in diabetes. It can change 
collagen type – IV enzyme function, structure and 
alter protein – glycation, reduced antioxidant level Figure 1 — General structure of Schiff base 




deactivate antiathero – Sclerotic enzyme32. Diabetes 
now days can be controlled via synthetic drugs. One 
of the drugs, i.e. Schiff base derived drugs have 
heteroatom azomethine or imine functionality and are 
known to possess novel activity in clinical use33,34. 
The presence of electron withdrawing or donating 
groups change the biological activity rate of Schiff 
base compounds35,36. The hetero atom or aromatic 
linkage presence in certain compounds provides 
broader biological activity37,38. Diabetes can be treated 
via the inhibition of alpha amylase enzyme involved 
in digestion of carbohydrate by lowering the glucose 
level in blood39. Around the world, diabetes patients 
have been multiplying. In the coming 25 years 
diabetes will be the most dangerous health killer. 
Around the world, people are investigating  
full treatment of diabetes mellitus via a synthetic  
drug or, natural derived40 therapies. Diabetes mellitus 
is disorder of carbohydrate metabolism characterized 
by hyperglycemia in which pancreas insulin level is 
altered and increase in blood sugar occurs41. It can be 
treated via an enzyme called alpha amylase42. Alpha 
amylase inhibition comprises the key step for the 
treatment of diabetes, intestinal absorption, digestion 




General procedure for synthesis of compounds 1–13 
Equimolar amounts of 2,4-dinitrophenylhydrazine 
and different aromatic as well as aliphatic  
aldehydes were refluxed in absolute methanol for 
about 4-6 hr at a temperature of 100°C. Anhydrous 
acetic acid was used as a catalyst to speed up the 
chemical reaction. Progress of reaction was monitored 
through TLC. In all the cases solid product was 
obtained, which was washed with water and further 
recrystallized with methanol to obtain compounds  
1-13 (Scheme I, Table I). 
Molecular docking studies 
Molecular Docking study was performed to explore 
the possible binding mode of the synthesized  
tested compounds against α-amylase enzyme using a 
well-developed modelling tool Molecular Operating 
Environment (MOE)44. The 3D coordinates for  
all compounds were generated using MOE-builder 
wizard and were protonated and energy minimized 
using the default parameters for molecular docking 
study in MOE. The crystal structure of α-amylase was 
retrieved from Protein Data Bank (www.rcsb.org) 
using PDB code 3BAJ. The structure was subjected to 
MOE for preparation to get the minimal energy 
conformation for molecular docking. Finally, the 
minimal energy conformation was used to perform 
docking using the default parameters of MOE and 
total five conformations for each ligand was allowed 
to generate. The ligands were ranked based on 
docking score; lower scores indicate more favorable 
poses. Finally, the predicted protein-ligand 
interactions (PLI) were analyzed for molecular 
interactions using PyMol v 1.7. 
 
Alpha amylase inhibitory assay 
The synthesized compounds 1–13 were evaluated 
for alpha - amylase activity. Inhibition Potential 
Activity was determined by Worthington – Enzymatic 
Manual Method45. The various diluted concentration 
of synthesized compound ranging from 10 – 100 µL 
prepared in Dimethylsulfoxide (DMSO). A sodium 
phosphate of 0.02 M, Concentration 500 µL buffer pH 
[Exact 6.9, including Sodium Chloride (NaCl) of 
0.006 M] containing alpha – amylase solution  
[0.5 mg/mL] for 15 minute at 25°C was incubated. 
Then starch solution of 1 % 500 µL added to each test 
– tube containing a sodium phosphate of 0.02 M 
buffer [Exact 6.9, including Sodium Chloride (NaCl) 
of 0.006 M]  then again  15  minute  at  25°C  reaction  
 
 
Scheme I — Synthesis of 2,4-diniyrophenyl hydrazone derivatives 




































mixture incubated, and control by addition 1.0 mL 
Dinitrosalicyclic Acid (DNS). The mixture obtained 
then transformed for incubation into water bath 
containing – boiled distilled water for 15 – minute 
cool to 20-25°C (room temperature). Again 10 mL 
distilled – water added to a reaction mixture for 
dilution. On UV – spectrophotometer absorbance  
at 540 nm are recorded (Sindhu et al., 2013; K.  
Balan et al., 2014). The control is acarbose in  
DMSO prepared same as above. The percent 
inhibition of the alpha – amylase activity is calculated 
on the following given Equation 1. 
 
Whereas A = after incubation absorbance of 
sample, amylase, starch. B = after incubation 
absorbance of sample, starch. X = after incubation 
absorbance of amylase and starch.  
Y = after incubation absorbance of starch only. 
 
Results and Discussion  
 
Chemistry 
The general route for the synthesis of the 
hydrazone derivatives(1-13) followed the general 
procedure which involves the use of round bottom 
flask, condenser and hot plate. A weighed amount of 
2,4-dinitrophenylhydrazine was taken in R.B 
containing methanol as a solvent and was refluxed 
with continuous stirring. After some time aldehyde 
was added to 2,4-dinitrophenylhydrazine to initiate 
the chemical reaction and few drops of acetic acid 
was added to the reaction mixture which act as a 
catalyst. The reaction was refluxed for 3 hrs at a 
temperature of about 100°C. The reaction was 
monitored with TLC and crystals of the obtained 
product was precipitated in ice cold water, washed 
and dried which were recrystallized from methanol to 
get pure crystals of final product. 
 
Synthetic Procedure 
All the synthesized compounds (1–13) were 
evaluated for alpha amylase activity. Inhibition 
Potential was determined by Worthington enzymatic 
manual method [45]. The various diluted 
concentration of synthesized compound prepared 
ranging from 10 – 100 µL was used in the assay.  





































antidiabetic activity in comparison with a standard 
acarbose alpha amylase inhibitor as shown in Table II 
were used the more potential activity in synthesized 
compound is shown by Compound 5(5-bromo-2-
methoxybenzylidene)-2-(2,4-dinitrophenyl)hydrazine) 
has IC50 12.16(µg/mL) value while compound  
6 (2,6-dimethoxybenzylidene)-2-(2,4 dinitrophenyl) 
hydrazine) show IC50 15.03(µg/mL) and 12 has  
IC50 16.42(µg/mL) while compound 13 (N-(2,4-
Dinitrophenyl)-N'-(4'-methoxybenzylidene)hydrazone) 
has IC50 23.78(µg/mL) while compound 11 (N-(2,4-
Dinitrophenyl)-N' (2',3',4'trihydroxybenzylidene) 
hydrazone) has IC50 27.27(µg/mL) and 4 N-(2,4-
Dinitrophenyl)-N'-(2',3'-dihydroxybenzylidene)hydrazone 
has IC50 31.54(µg/mL) respectively. While the 
standard antidiabetic acarbose used in comparison to 
the above compound showed a less inhibition 
potential have IC50 42.47(µg/mL) shown in (Table II). 
All other remaining compound is also active in 
activity but show less potential in comparison to the 
standard used shown (Figure 2 and Figure 3). 
 
Molecular docking  
In the current study, we have performed molecular 
docking study to evaluate the inhibition potential of 
all the synthesized compounds against α-amylase 
enzyme. The molecular docking results indicate the 
compounds potentially bind in the catalytic site of the 
enzyme. The surface representation of the enzyme 
with zoomed-in the catalytic site was depicted in 
Figure 4A. We have noticed that the compounds 
bearing electron-withdrawing group (EWG’s) showed 
best binding potential, while bearing electron-
donating groups (EDG) showed less activity, whereas 
these groups make the aromatic ring electron-poor 
(δ+) relative to benzene, therefore, they strongly 
deactivate the ring and further compel the compounds 
to adopt favorable interactions, and hence raised the 
inhibitory activity. The correlation among IC50 and 
predicted docking score (S) were plotted and depicted 
in Figure 4B. The protein-ligand interaction (PLI) 
profile for potent compounds revealed that 5 showed 
excellent amylase inhibitory potential and adopted 
favorable interaction with catalytic residues including; 
the electrically charged positive and negative residues 
R343, K322 and hydrophobic W388 as shown in 
Figure 4C. 
The high potency might be due to the EWG (Br)  
at -meta position whose have higher magnitude of 
deactivation than the phenyl and OCH3 group 
respectively and, hence raising the enzymatic 
potential. The 2nd and 3rd ranked compound in the 
series (6 and 12) which also displayed average α-
amylase potential also showed some favorable key 
interactions with catalytic residues includes; R343, 
Q389 and W388 as shown in Figure 4D and 
Figure 4E respectively. The less potential might be 
due to the strong and weak magnitude of deactivation 
Table II — IC50valuesof synthesized compounds 1–13 
Compd IC50 (µg/mL) Compd IC50 (µg/mL) 
1 86.31 8 52.36 
2 87.96 9 78.24 
3 53.61 10 55.19 
4 31.54 11 27.27 
5 12.16 12 16.42 
6 15.03 13 23.78 






Figure 2 — Standard acarbose value at various concentrations 
 
Figure 3 — Comparison of median inhibitory concentration
values of compounds 1–13 




of EWG and EDG attached respectively. Our 
experimental activity correlates well with molecular 
docking. 
Concluded that the more potential activity of these 
compounds (5, 6 and 12) is due to electron donating 
groups such as methoxy and methyl group is present 
in their basic skeleton structure. While other 
remaining compound contain different electron-
withdrawing group such as chlorine and nitro groups 
therefore possess less potent inhibition activity37,38. 
The different aromatic or, heteroatom linking in a 
certain compound reported with a broader biological 
activity. Also, the biological activity of tested 
compound is always different35,36 it is because of 
structural-relationship when it contain different 
electron donating or, withdrawing group. The 
electron-withdrawing group showed less potency 
while in comparison to electron-donating is reported 
with highest potential activity. 
 
Conclusion 
The current studies have shown that compounds 5 
(IC50 =12.16µg/mL), 6 (IC50=15.03µg/mL), and 12 
(IC50 =16.42 µg/mL), are found to be the more potent 
alpha amylase inhibitors as compared to the standard 
acarbose (IC50 =42.47µg/mL). These compounds may 
provide better leads for preparation of novel alpha-
amylase inhibitors. Further assessment of these 
compounds is important and can be of great help in 
the discovery of new antidiabetic drugs. 
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